A Phase 1, Randomized, Open-label, 2-way Crossover Study in Healthy East Asian and Caucasian Volunteers to Evaluate the Relative Bioavailability of A New Capsule Formulation of TG-2349 Compared to the Original Formulation of TG-2349 Oral Solution

Trial Profile

A Phase 1, Randomized, Open-label, 2-way Crossover Study in Healthy East Asian and Caucasian Volunteers to Evaluate the Relative Bioavailability of A New Capsule Formulation of TG-2349 Compared to the Original Formulation of TG-2349 Oral Solution

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Dec 2014

At a glance

  • Drugs Furaprevir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors TaiGen Biotechnology
  • Most Recent Events

    • 18 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Nov 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 27 Nov 2014 Planned primary completion date changed from 1 Dec 2015 to 1 May 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top